Allogeneic Hematopoietic Stem Cell Transplant Using Mismatched/Haploidentical Donors

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 11, 2007, Pages 1249-1267

  Koh, Liang Piu ^a,b   Rizzieri, David A ^a   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

GVHD; Immune reconstruction; T cell depletion

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN RECEPTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; SEMUSTINE; SIPLIZUMAB; STEROID; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CANCER SURVIVAL; CD34 SELECTION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENGRAFTMENT; EVIDENCE BASED MEDICINE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HLA MATCHING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LYMPHOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUROTOXICITY; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; T CELL DEPLETION; TRANSPLANTATION TOLERANCE; WHOLE BODY RADIATION;

GRAFT SURVIVAL; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LYMPHOCYTE DEPLETION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 35348816122     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.08.003     Document Type: Review

References (113)

1. Confer D.L. Unrelated marrow donor registries. Curr Opin Hematol 4 (1997) 408-412
2. Beatty P.G., Mori M., and Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60 (1995) 778-783
3. Hansen J.A., Petersdorf E., Martin P.J., and Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 157 (1997) 141-151
4. nd ed. (1999), Blackwell Science, Malden, MA 503-512
5. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 96 (2000) 4096-4102
6. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95 (2000) 2219-2225
7. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 14 (2000) 502-504
8. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
9. Aversa F., Velardi A., Tabilio A., et al. Haploidentical stem cell transplantation in leukemia. Blood Rev 15 (2001) 111-119
10. Rocha V., Wagner Jr. J.E., Sobocinkski K.A., et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N. Engl J Med 342 (2000) 1846-1854
11. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344 (2001) 1815-1822
12. Long G.D., Laughlin M., Madan B., et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 9 (2003) 772-780
13. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29 (1990) 79-91
14. Kernan N.A., Flomenberg N., Dupont B., and O'Reilly R.J. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 43 (1987) 842-847
15. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340 (1999) 508-516
16. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985) 765-771
17. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320 (1989) 197-204
18. Powles R.L., Morgenstern G.R., Kay H.E., et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1 (1983) 612-615
19. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15 (1997) 1767-1777
20. Kanda Y., Chiba S., Hirai H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 (2003) 1541-1547
21. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107 (2006) 3065-3073
22. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
23. Soiffer R.J., Mauch P., Tarbell N.J., et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 7 (1991) 23-33
24. Reisner Y., and Martelli M.F. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 16 (1995) 437-440
25. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84 (1994) 3948-3955
26. Henslee-Downey P.J., Parrish R.S., MacDonald J.S., et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 61 (1996) 738-745
27. + T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant 3 (1997) 11-17
28. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89 (1997) 3864-3872
29. Mehta J., Singhal S., Gee A.P., et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33 (2004) 389-396
30. Drobyski W.R., Klein J., Flomenberg N., et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99 (2002) 806-814
31. Bachar-Lustig E., Rachamim N., Li H.W., et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1 (1995) 1268-7123
32. Tabilio A., Falzetti F., Giannoni C., et al. Stem cell mobilization in normal donors. J. Hematother 6 (1997) 227-234
33. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
34. Schumm P., Lang P., Taylor G., et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J. Hematother 8 (1999) 209-218
35. Handgretinger R., Lang P., Ihm K., et al. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 29 (2002) 731-736
36. + progenitors for autologous and allogeneic transplantation in children. Bone Marrow Transplant 24 (1999) 583-589
37. Handgretinger R., Schumm M., Lang P., et al. Transplantation of megadoses of purified haploidentical stem cells. Ann. N Y Acad. Sci 872 (1999) 351-361
38. Handgretinger R., Klingebiel K., Lang P., et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27 (2001) 777-783
39. Klingebiel T., Handgretinger R., Lang P., et al. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 18 (2004) 181-192
40. Terenzi A., Aristei C., Aversa F., et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 28 (1996) 3101
41. Pan L., Delmonte J., Jalonen C.K., et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86 (1995) 4422-4429
42. Volpi I., Perruccio K., Tosti A., et al. Post-grafting granulocyte colony-stimulating factor administration impairs functional immune recovery in recipients of HLA haplotype-mismatched hematopoietic transplants. Blood 97 (2001) 2514-2521
43. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin Oncol 23 (2005) 3447-3454
44. Lang P., Greil J., Bader P., et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 33 (2004) 281-287
45. Kato S., Yabe H., Yasui M., et al. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant 26 (2000) 1281-1290
46. Walker I., Shehata N., Cantin G., et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis 33 (2004) 222-226
47. Guinan E.C., Boussiotis V.A., Neuberg D., et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340 (1999) 1704-1714
48. Lang P., Bader P., Schumm M., et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 124 (2004) 72-79
49. Kawano Y., Takaue Y., Watanabe A., et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 92 (1998) 3123-3130
50. Peters C., Matthes-Martin S., Fritsch G., et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 13 (1999) 2070-2078
51. Passweg Jr., Kuhne T., Gregor M M., et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplantation 26 (2000) 1033-1036
52. Henslee-Downey P.J. Allogeneic transplantation across major HLA barriers. Best Pract Res Clin Haematol 14 (2001) 741-754
53. Barfield R.C., Otto M., Houston J., et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6 (2004) 1-6
54. Hale G., Kimberly K., Lovins R., et al. CD3 Depleted hematopoietic peripheral blood stem cell grafts in children with refractory hematologic malignancies undergoing transplantation from mismatched related donors. [abstract]. Blood 106 (2005) 451b
55. Bethge W.A., Haegele M., Faul C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 34 (2006) 1746-1752
56. Handgretinger R., Chen X., Pfeiffer M., et al. Feasability and outcome of reduced intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 1106 (2007) 279-289
57. Pelot M.R., Pearson D.A., Swenson K., et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 5 (1999) 133-143
58. Spitzer T.R., McAfee S.L., Dey B.R., et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75 (2003) 1448-1751
59. Dey B.R., and Spitzer T.R. Current status of haploidentical stem cell transplantation. Br J Haematol 135 (2006) 423-437
60. Spitzer T.R. Haploidentical stem cell transplantation: the always present but overlooked donor. Hematology (Am Soc Hematol Educ Program) (2005) 390-395
61. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002) 377-386
62. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12 (2006) 1073-1084
63. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
64. Kanda Y., Oshima K., Asano-Mori Y., et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79 (2005) 1351-1357
65. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25 (2007) 690-697
66. Ljunggren H.G., and Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 11 (1990) 237-244
67. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
68. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007) 433-440
69. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172 (2004) 644-650
70. Leung W., Iyengar R., Triplett B., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174 (2005) 6540-6545
71. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
72. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
73. Bornhauser M., Schwerdtfeger R., Martin H., et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 (2004) 2860-2861
74. Beelen D.W., Ottinger H.D., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 (2005) 2594-2600
75. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 (2004) 204-211
76. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
77. Ruggeri L., Mancusi A., Burchielli E., et al. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 19 (2007) 142-147
78. Tamaki S., Ichinohe T., Matsuo K., et al. Superior survival of blood and marrow stem cell transplants given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant 28 (2001) 375-380
79. van Rood J.J., Loberiza F.R., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 96 (2002) 1572-1577
80. Ichinohe T., Uchiyama T., Shimazaki C., et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104 (2004) 3821-3828
81. Ochiai N., Shimazaki C., Fuchida S., et al. Successful non-T-cell depleted HLA haplo-identical 3-loci mismatched hematopoietic stem cell transplantation from mother to son based on the fetomaternal microchimerism in chronic myelogenous leukemia. Bone Marrow Transplant 30 (2002) 793-796
82. Shimazaki C., Ochiai N., Uchida R., et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood 101 (2003) 3334-3336
83. Obama K., Utsunomiya A., Takatsuka Y., et al. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant 34 (2004) 897-899
84. Shimazaki C., Fuchida S., Ochiai N., et al. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism. Br J Haematol 127 (2004) 474-475
85. Dazzi F., Szydlo R.M., Cross N.C., et al. Durability of responses following donor lymphocytes infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96 (2000) 2712-2716
86. Porter D.L., Collins R.H., Hardy C., et al. Treatment of relapsed leukemia after unrelated unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95 (2000) 1214-1221
87. Wu B.Y., Guo K.Y., Song C.Y., et al. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplant 26 (2000) 691-693
88. Lewalle P., Triffet A., Delforge A., et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 31 (2003) 39-44
89. Pati A.R., Godder K., Lamb L., et al. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 15 (1995) 979-981
90. Or R., Hadar E., Bitan M., et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1295-1301
91. Huang X.J., Liu D.H., Liu K.Y., et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92 (2007) 414-417
92. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8 (2002) 625-632
93. Passweg J.R., Tichelli A., Meyer-Monard S., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18 (2004) 1835-1838
94. Passweg J.R., Stern M., Koehl U., et al. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 35 (2005) 637-643
95. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 91 (1998) 3646-3653
96. Eyrich M., Lang P., Lal S., et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. Br J Haematol 114 (2001) 422-432
97. Cavazzana-Calvo M., Fromont C., Le D.F., et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 50 (1990) 1-7
98. Harris D.T., Sakiestewa D., Lyons C., et al. Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow Transplant 23 (1999) 137-144
99. Koh M.B., Prentice H.G., Corbo M., et al. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol 118 (2002) 108-116
100. Hartwig U.F., Robbers M., Wickenhauser C., et al. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 99 (2002) 3041-3049
101. Chen B.J., Cui X., Liu C., and Chao N.J. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99 (2002) 3083-3088
102. Andre-Schmutz I., Le D.F., Hacein-Bey-Abina S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360 (2002) 130-137
103. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
104. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006) 1797-1808
105. Ash R.C., Casper J.T., Christopher R., et al. Successful allogeneic transplantation of T-cell depleted bone marrow from closely matched unrelated donors. N Engl J Med 322 (1990) 485-494
106. Locatelli F., Rocha V., Chastang C., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 93 (1999) 3662-3671
107. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001) 2962-2971
108. Koh L.P., and Chao N.J. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 10 (2004) 1-22
109. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
110. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
111. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic leukemia. J Clin Oncol 23 (2005) 3819-3829
112. Chao N.J., Koh L.P., Long G.D., et al. Adult recipients of umbilical cord blood transplantation following non-myeloablative preparative regimen. Biol Blood Marrow Transplant 10 (2004) 569-575
113. Miyakoshi S., Yuji K., Kami M., et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin. Cancer Res 10 (2004) 3586-3592